Lincoln Pharmaceuticals sees a significant rise in profit and revenue in the June quarter, backed by higher sales, improved margins, and plans to boost exports from its Gujarat manufacturing base to 90 countries in the next few years.
Lincoln Pharmaceuticals posted a stronger first quarter as higher sales and improved margins lifted profit for the three months to 30 June 2026. The drugmaker said consolidated net profit rose 30.9% year on year to ₹36.23 crore, while total income increased 19.02% to ₹201.55 crore. EBITDA, or earnings before interest, tax, depreciation and amortisation, climbed 32.29% to ₹51.70 crore, and earnings per share came in at ₹18.09. The result marks an improvement on the same quarter a year earlier, when profit was ₹27.68 crore and income was ₹169.34 crore.
The latest numbers come after a mixed but broadly improving run for the Ahmedabad-based company. Business Standard reported that consolidated net profit in the March 2026 quarter edged up to ₹11.63 crore from ₹11.58 crore a quarter earlier, while full-year net profit for the year ended March 2026 rose 6.73% to ₹87.89 crore and sales increased 7.67% to ₹671.03 crore. Moneycontrol had earlier reported that Lincoln’s standalone net profit rose 16.93% in the first quarter of FY26, with income at ₹169.34 crore and EBITDA at ₹39.08 crore.
Lincoln is targeting ₹1,000 crore in revenue within three years, backed by annual growth of 15% to 18%, according to the company’s statement. It expects demand from cardiac, diabetes, dermatology and ENT treatments to support that plan while it widens its domestic and overseas reach. The company said it currently exports to more than 60 countries and wants that to rise to 90 within two to three years, as it strengthens its presence in regulated and semi-regulated markets.
The company’s manufacturing base at Khatraj in Gujarat remains central to that strategy. Lincoln says the site holds EU-GMP, TGA, WHO-GMP and ISO certifications, and that it has more than 600 formulations across 15 therapeutic areas, with a wider portfolio of more than 1,700 registered products. CRISIL Ratings has reaffirmed the company’s A/Stable and A1 ratings, citing its established market position and healthy financial profile, though it also flagged working-capital, regulatory and competitive pressures.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
